The global in vivo toxicology market size is projected to reach USD 6.6 billion by 2025 from USD 5.0 billion in 2020, at a CAGR of 5.5% during the forecast period. Market growth is driven largely by the increasing pharmaceutical R&D activities, innovations in animal models, the development of exclusive in vivo toxicology tests, and the increasing demand for personalized medicine. • By Product, the consumables accounted for the largest share of the in vivo toxicology market.
The in vivo toxicology market is categorized into instruments and consumables.The consumables segment is further categorized into animal models and reagents & kits.
Animal models is sub segmented into mice, rat and other animals.The consumables segment accounted for the largest share of the in vivo toxicology market in 2019.
The widespread use of reagents & kits in research activities, increase in funds for research projects, and their extensive application in the in vivo toxicology studies are fueling the growth of this segment.
By toxicity endpoint, the immunotoxicity segment accounted for the largest share of the in vivo toxicology market.
The global in vivo toxicology market is segmented into immunotoxicity, systemic toxicity, carcinogenicity, genotoxicity, developmental & reproductive toxicity (DART), and other toxicity endpoints (includes organ toxicity, endocrine disruptor toxicity, juvenile toxicity, phototoxicity, ocular toxicity, and skin irritation). In 2019, the immunotoxicity segment accounted for the largest share of the global in vivo toxicology market, followed by the systemic toxicity segment.The rising demand for the development of biologics and biosimilars is driving the growth of the immunotoxicity segment
By test type, chronic test type segment accounted for the largest share of the in vivo toxicology market The global in vivo toxicology market is segmented into acute, sub-acute, sub-chronic, and chronic test type.The chronic test type segment is expected to dominate the market during the forecast period.
In 2019, the chronic test type segment held the largest share of the market, followed by sub-chronic test type.Increasing research on drugs used for longer-duration therapy such as anti-cancer, anti-convulsive, anti-arthritis, and anti-hypertensives drives the growth of the chronic test type market.
By End user, Academic and Research Institutes accounted for the largest share of the in vivo toxicology market The global in vivo toxicology market has been broadly segmented into academic & research institutes, pharmaceutical & biotechnology companies, contract research organizations, and other end users (cosmetic companies and food laboratories). The academic and research institutes segment accounted for the largest share of the in vivo toxicology market in 2019. The increasing number of research activities in the field of in vivo toxicology and funding to the academic and research institutes to conduct in vivo toxicology research are the factors responsible for the largest share of the segment Asia Pacific: The fastest-growing region in the in vivo toxicology market. The Asia Pacific market is projected to grow at the highest CAGR during the forecast period.Several global pharmaceutical firms have entered the APAC market to tap the significant growth opportunities in emerging Asian countries and lower their production costs by shifting their drug discovery R&D operations and manufacturing to the region.
A large number of qualified researchers and low-cost operations in APAC countries, such as India and China, are some of the major factors supporting this trend.
North America: The largest share of the in vivo toxicology market.
North America, which includes the US and Canada, accounted for the largest share of the in vivo toxicology market. The large share of the North America region can be attributed to the presence of major players operating in the in vivo toxicology market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.
Breakdown of primaries The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows: • By Respondent– Supply Side- 80%, Demand Side-20% • By Designation— Executives- 25%, CXOs- 20%, Managers - 55% • By Region— North America - 50%, Europe - 20%, APAC – 20%, RoW- 10%
The in vivo toxicology market is dominated by a few globally established players such as Charles River Laboratories (US), The Jackson Laboratory (US), Envigo (US), Taconic Biosciences, Inc. (US), and JANVIER LABS (France), Thermo Fisher Scientific (US), Danaher Corporation (US), Waters Corporation (US), Agilent Technologies (US), Shimadzu Corporation (Japan), Bruker Corporation (US), PerkinElmer (US). Other prominent players include Merck KGaA (Germany), GE Healthcare (US), and Bio-Rad Laboratories (US), genOway (France), Cyagen Biosciences (US), GVK BIO (India), PolyGene (Switzerland), Crown Biosciences (US), TransCure bioServices (France), Ozgene Pty Ltd. (Australia),and Harbour BioMed (US)
Research Coverage: The report segments the in vivo toxicology market based on region (North America, Asia Pacific, Europe, Latin America and Middle East & Africa), product (instruments, consumables((Animal models (mice, rat and other animal odels), Reagents & kits)) test type (acute, sub-acute, sub-chronic, and chronic ) , Testing facility (outsourced and in-house), toxicity end point (immunotoxicity, systemic toxicity, carcinogenicity, end user(academic and research institutes, pharmaceutical & biotechnology companies, contract research organizations, and other end users).Company type (Tier 1, tier 2, Tier 3 providers of in vivo toxicology instruments and services).
The report also provides a comprehensive review of market drivers, challenges, and opportunities in the in vivo toxicology market.
Key Benefits of Buying the Report: The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments.This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies.
The report also helps stakeholders understand the pulse of the in vivo toxicology market and provides them information on key market drivers, challenges, and opportunities.
Our reports have been used by over 10K customers, including:
The global Patient-Derived Xenograft/PDX models market size is projected to reach USD 299 million by 2026 from USD 140 million in 2021, at a CAGR of 16.4% during the forecast period. Market growth is driven mainly by factors such as growing demand for personalized medicine, continuous support for cancer research, and growth in pharma R&D....
The global custom antibody market is projected to reach USD 652 million by 2026 from USD 393 million in 2021, at a CAGR of 10.6% during the forecast period.The increasing demand for protein therapeutics is expected to drive the custom antibody market in the coming years. On the other hand, the need for significant capital investments and long...
The cell-based assays market is projected to reach USD 22.0 billion by 2025 from USD 14.9 billion in 2020, at a CAGR of 8.1% during the forecast period. The growing preference for cell-based assays in drug discovery, increasing funding for cell-based research, and growth in the number of drug discovery activities are the key factors supporting...
The global high-throughput screening market size is projected to reach USD 26.4 billion by 2025 from USD 15.3 billion in 2020, at a CAGR of 11.5% during the forecast period. The growth in this market is primarily attributed to increasing R&D spending by pharmaceutical & biotechnology companies, technological advancements in high-throughput...
The quantitative structure-activity relationship (QSAR) market is expected to reach US$ 1,888.5 million by 2027 from US$ 1,388.1 million in 2019; it is estimated to grow at a CAGR of 4.0% during 2020–2027. The market growth is mainly attributed to the increasing adoption rate of modeling tools in drug discovery and rising investments for drug...
The Global Electronic Clinical Outcome Assessment Solution Market (eCOA) size is expected to reach $2.4 billion by 2026, rising at a market growth of 19% CAGR during the forecast period. Electronic clinical outcome assessment (eCOA) refers to a system that is capable of measuring mental state, patient symptom, and the prognosis of a disease....
Certain factors that are driving the market growth include rising healthcare expenditure, growing burden of chronic diseases and advances in drug discovery and development. The burden of chronic diseases is increasing worldwide. According to WHO, chronic diseases have always been a massive global challenge, and they account for approximately...
The microplate reader market was valued at US$ 534.5 million in 2019 and is projected to reach US$ 704.4 million by 2027; it is expected to grow at a CAGR of 3.6% during 2020–2027. The market is attributed to increasing research and development in the pharmaceuticals industry, and escalating incidence of infectious diseases. However, high...
An organ-on-a-chip is a microfluidic cell culture device that contains continuously perfused chambers. This chip develops a narrow channel for the blood and airflow in organs, such as the lung, gut, liver, heart, and other organs. Such devices produce multiple levels of tissue and organ functionalities, which are not feasible using conventional...
294 pages •
By Roots Analysis Private Ltd.
• Nov 2020
The drug discovery process, which includes the identification of a relevant biological target and a corresponding pharmacological lead, is crucial to the clinical success of a drug candidate. Considering the growing complexity of modern pharmacology, the discovery of viable therapeutic candidates is very demanding,...
Pharmaceutical R&D Expenditure
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.